Mitchell JM
Department of Neurology, University of California, San Francisco, California, San Francisco, USA.
ArticlePsilocybin
Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.
ArticleAyahuasca
Investigating Safety Concerns and Harm Reduction in Entheogenic Churches: The Case for Community-Based Participatory Research.
ArticlePsilocybin
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
ArticleKetamine
Ketamine-Assisted Recovery (KARE): protocol for an open-label pilot trial of ketamine-assisted psychotherapy for publicly insured patients with methamphetamine use disorder and HIV risks.
ArticleMDMA
A systematic review of income and education reporting in psychedelic clinical trials.
ArticleMDMA
Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.
ArticlePsychedelics
Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options.
PreprintPsilocybin
Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits
ArticleMDMA
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
ArticlePsychedelics
Psychedelics in Addiction Treatment-Navigating a Sociopolitical Rift.
ArticleMDMA
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
ArticlePsychedelics
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
ArticleMDMA
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
ArticlePsilocybin